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A study of seroprevalence of rubella IgG in Maltese adolescents 

Dennis Falzon*, Mark Muscat**, Ray Busuttil***, Alfred Portelli**** 
ABSTRACT: Objective - To determine the seroprevalence of rubella IgG antibodies in Maltese 
adolescents. Design - A cross-sectional study, with mailed questionnaire and blood sampling. 
SUbjects - 172 individuals aged 14-15 years from Malta and Gozo. Outcome variables - Prevalence 
of vaccination and seropositivity (IgG) for rubella. Results - 85% were vaccinated; seropositivity 
was detected in 168 youths (97.7%). Conclusion - The study showed a high level of detectable 
humoral immunity to rubella. This could not be definitively attributed to vaccination alone. 
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Rubella is a directly communicable condition of man 
caused by a Togavirus I. It is an exanthem of childhood, 
most disease is mild and up to 50% of infections are 
asymptomatic2. The public health significance of rubella 
lies mainly in its teratogenic potential, although the 
primary infection may rarely cause thrombocytopaenic 
purpura, encephalopathy and panencephalitis3. Up to 
90% of all foetuses infected in utero during the first 8-10 
weeks of pregnancy suffer damage, commonly involving 
mUltiple, vital functions4 . Congenital rubella syndrome 
became notifiable in Malta in August 19905. Since then 
two cases have been notified to the Department of Public 
Health, both in 1996. 
Rubella became notifiable under Maltese law in 19786 , 
and legal provisions for vaccination of female children 
aged 10 to 13 years were mandated in 19897. Figure 1 
depicts a steady decline in incidence of notified rubella 
from the mid-80s, a trend which was sharply reversed in 
1995 with a twentyfold increase (416 cases) over the 
previous year8. Table 1 presents the age and sex profile 
of notified cases from 1986-1995. The male to female 
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for the 1995 episode compared to the previous 9 years. 
The mean age (recorded in 84% of subjects) was 17.8 
years (range 0.5-72). The cases originated from a wide 
geographic distribution in Malta. The episode was not 
virologically confirmed. It led, however, to concerns 
about the integrity of local herd immunity to rubella and 
it prompted the study being presented. 
Subjects and Methods 
The aim of the study was to determine the proportion 
of Maltese adolescents who had detectable levels of 
rubella IgG in the blood. 
The study was planned by the Department of Health 
and ethical approval was obtained from the Medical 
Council in 1996. It was decided to select study 
participants from Maltese and Gozitan youths aged 14­
15 years. The sampling frame consisted of the national 
birth cohort of 1982 available on a database. 500 
eligible individuals were selected from this list using a 
cumputerised random sampler (Epi Info 6.02). Selection 
was independent of sex, past history of rubella infection 
or vaccination. 
Questionnaires were posted to all prospective 
candidates in December 1996. The 
questionnaire requested those identified to 
complete details of demography (name, 
date of birth, address) and status of 
vaccine and past infection. Parental 
consent was requested concomitantly. A 
reminder was sent to non-respondents in 
January 1997 . By early February, 196 
participants (39.2% response) had 
N M ~ LO CD ,..... 
(J) 0> (J) (J) 0> (J) completed questionnaires. As the total 
(J) (J) (J) 0> 0> 0> 
1982 birth cohort surviving to end 
December 1994 was estimated as 5871 9• 
the sanlple therefore approximated 3.3% Fig. 1 - Notified rubella, Malta, 1979-1997. (NB V-axis is on a Log 1 0 scale) 
of the persons at that age. Source : Departmellf ofHealth Information. Malta. 
Respondents were given appointments to 
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Table 1 - Age and Sex profile of Notified 
Rubella cases in Malta, 1986-1995 
Year Cases M:F C. incidence Mean Range 
Ratio (per 104 pop) Age (y) (y) 
1986 270 1.37: I 7.86 7.5 0.3-38 
1987 56 1.43:1 1.62 9.0 0.6-42 
1988 28 0.87:1 0.80 4.4 0.5-20 
1989 30 0.76:1 0.85 6.6 0.4-60 
1990 14 0.27:1 0.39 8.0 0.4-45 
1991 14 1.33: 1 0.39 9.0 0.6-23 
1992 6 0.2:1 0.17 4.4 0.5-10 
1993 17 0.89:1 0.46 9.8 0.8-38 
1994 20 1.5: 1 0.54 14.0 1-30 
1995 416 1:0.29 11.18 17.8 0.5-72 
Source: Department ofHealth Information. 
Central Office ofStatistics. Malta. 
attend health centres at Paola, Mosta, Rabat or Gzira for 
completion of the questionnaire and for blood sampling. 
These encounters were organised on two Saturdays to 
avoid interference with schooling. A 'mop-up' session 
was held on one evening for those who could not make it 
otherwise. Gozo participants (nine) were called up to 
Victoria Health OfficelO. Data was entered and analysed 
using Epi Info Ver 6.02 (CDC/WHO, October 1994), 
and MS Excel Ver 4.0. Venous blood (5 ml) was 
collected from each participant by the first two authors 
and another doctor in Gozo and processed at the 
Virology Laboratory at St Luke's Hospital, G'Mangia. 
The serology was performed using Abbott IMx R 
Rubella IgG 2.0 Antibody assay based on the 
Micropartic1e Enzyme Immunoassay (MEIA) to rubella. 
The breakpoint for seropositivity using this qu.antitative 
analysis is 10 IU/ml, which is the accepted cut-off for 
immune status1 I . Participants were informed of their 
sero-status by letter and those testing negative were 
offered vaccination. 
Findings 
A total of 172 participants were tested for the presence 
of rubella specific antibodies. The male to female ratio 
was 1:0.91. Out of these, 147 (85%) were vaccinated, 
mostly (75%) at school, but also by their GP (10%) and 
at health centres (15%). Of the 143 in whom the date of 
vaccination was established, 78% were vaccinated in 
1995. 109 of vaccinees gave no previous history of 
rubella. Twenty-six were vaccinated despite a previous 
history of rubella-like disease. 
Out of the 172 tested, 168 (97.7%) had antibodies for 
rubella. Table 2 gives the results by sex, No statistically 
significant difference between the sexes could be shown. 
Only 4 participants tested negative, all of whom reported 
no history of rubella or rubella vaccination (Table 3). 
Conclusions 
1. The study showed a high prevalence of humoral 
immunity against rubella (0.97, 90% Cl 0.95-0.99) 
amongst Maltese females in the pre-childbearing age­
group. 
2. The study could not differentiate between vaccine 
induced immunity or that imparted by disease. 
3. Those who gave a history of rubella or vaccination 
or both had a statistically significant increased chance of 
being seropositive in contrast to those whose exposure 
was negative or unestablished (Table 3). The basic 
assumption here is that infection, vaccination or both 
together are equivalent opportunities for developing 
antibodies, and that no history or an unestablished 
history signifies no opportunity for development of 
antibody. 
Table 2 - Detection of rubella IgG by sex, Malta, 
1997 (n=172). 
Serology result Females Males Total 
Negative 3 1 4 
Positive 79 89 168 
Total 82 90 172 
Proportion seronegative = 0.023 .. 95% Cl 0.006-0.059 
(after Zar) 
Fisher exact }-tailed P-value =0.276 
Table 3 - Serology results by vaccination status and 
history of rubella, Malta, 1997 (n=172). 
Serology History of Rubella and Vaccination 
Rubella Rubella Only Vaccine Only None 
+ Vaccine 
Positive 26 7* 121** 14*** 
Negative 0 o o 4 
* 2 had vaccine status unknown 
** 12 had past rubella history unknown 
*** history of rubella or vaccine negative or not 
established 
Proportion seronegative in unexposed group = 0.222 .. 95% 

Cl 0.064-0.476 (after Zar) 

Fisher exact P () st 3 elms vs last elm) = O.OOO} 

Discussion 
Active immunity after natural infection and 
vaccination is usually permanent. However, the 
immunity developing post vaccination is less robust. 
Where vacCination coverage in childhood is high, 
rubella outbreaks are seen in older persons l2 . 
In Maltese state health services, Measles-Mumps­
Rubella vaccine is given at 15 months and at 11-13 years 
of age l3 . Up to May 1989, vaccination was offered to 
girls in their last year of primary school or the first year 
of secondary school and to women before marriage. A 
wider and more comprehensive strategy, which also 
included boys, was adopted from May 1989 14 . 
Rubella in children is unlikely to occur in the early 
years following vaccination. In the 1995 episode the 
average age of those affected was relatively high. This 
is probably due to high vaccination coverage in 
childhood. In fact, the group studied had an 85% 
coverage of at least one dose of rubella vaccine. In 
contrast, 70% of the 1993 national birth cohort were 
covered for their 15-month dose of MMR by July 
1997 15 . The difference between the groups may be 
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attributed to: 
• increased public awareness of rubella-associated 
congenital defects in children born to non-immune 
mothers; 
• better opportunity for vaccination in schools rather 
than a separate encounter at a young age; 
• more complete notification of vaccination in this 
group in contrast to the I5-month group; 
• bias from the sample in this study which may have 
over-represented the motivated (read protected) 
fraction of the population. 
Recommendations 
Although the study design precludes direct correlation 
of immune status to degree of vaccine cover, it is 
reasonable to conclude that a good proportion of 
protection is directly attributed to vaccination. Hence, 
the authors stress that there is no place for complacency 
with continued vaccination. Vaccination is still 
recommended for children with previous history of 
rubelliform illness. 
The study as performed may be repeated in the future 
either to follow up the same birth cohort to assess any 
variation in immune status, or else in subjects of the 
same age group to measure variations over years in 
similar populations. The authors also feel that this study 
should be complemented by at least one other study 
investigating antibody protection in females at different 
stages of the childbearing period - the ultimate target 
population for anti-rubella measures. Given the high 
level of seroprevalence found in young people in this 
study, the determination of short-term efficacy of 
vaccination in this age-group may be technically 
difficult. 
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